TRML Rasio cepet Tourmaline Bio, Inc.

The Tourmaline Bio, Inc. (TRML) price chart demonstrates the current coefficient 23.95. The business relies on developing antibodies for various inflammatory pathologies, which reduces dependence on the success of a single trial. Tourmaline Bio, Inc. (TRML) creates unique therapies for orphan diseases, avoiding price wars with competitors. The operating model is based on outsourcing production and research to third-party contractors to optimize headcount.

Seeking to carve out a niche in the orphan rheumatological disorders segment, Tourmaline Bio (TRML) requires stable funding for prolonged R&D cycles. The quick ratio quantifies this potential by excluding illiquid inventories and assessing the company's ability to meet short-term obligations solely through cash and accounts receivable, reflecting the business's actual financial stability on this chart.